Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149)
 on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary
 Disease (COPD).
Inclusion Criteria:

 -  Diagnosis of moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD)
 stage II or stage III according to the Global Initiative for Chronic Obstructive Lung
 Disease (GOLD) Guidelines (2009)

 -  Qualifying spirometry, Forced Expiratory Volume in one second (FEV1) and
 post-bronchodilator FEV1/FVC (Forced Vital capacity)

 -  Smoking history ≥ 10 pack years

 Exclusion Criteria:

 -  Pregnant women or nursing mothers or women of child-bearing potential not using
 adequate contraception

 -  Cardiac abnormality

 -  History of asthma

 -  Contraindications to cardiopulmonary exercise testing

 -  Participation in active phase of pulmonary rehabilitation program

 -  History of cancer within the past 5 years

 Other protocol-defined inclusion/exclusion criteria may apply